Chiasma (New York and Israel) is a biopharmaceutical company developing oral drugs that were previously only available by injection, providing patients with pain-free medications that are self-administered. The company’s lead product is in Phase III clinical trials for the treatment of acromegaly.
Octreolin® is an oral octreotide acetate in clinical development for patients with acromegaly, a hormonal disorder that results from an excess of growth hormone. Today octreotide is typically administered by large bore intra-muscular needle injections. Our oral octreotide has the potential to improve the quality of life of acromegaly patients. A Phase 3 study began in Q4 2011. More…
At Chiasma, we recognize the challenges of living with a chronic disease. We are focused on developing Octreolin, an investigational oral octreotide therapy. This is the only oral somatostatin analog treatment for acromegaly currently in clinical development. For more information about Octreolin or how to enroll to our Phase 3 clinical study please click here. More…